about
Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks' follow-upLong-Term Antiretroviral Treatment Adherence in HIV-Infected Adolescents and Adults in Uganda: A Qualitative StudyClinical evaluation of a dried blood spot assay for atazanavirIncidence of atazanavir-associated hyperbilirubinemia in Korean HIV patients: 30 months follow-up results in a population with low UDP-glucuronosyltransferase1A1*28 allele frequency.The New Epidemiology of HIV-Related Kidney Disease.CYP3A-mediated generation of aldehyde and hydrazine in atazanavir metabolism.Alterations in thigh subcutaneous adipose tissue gene expression in protease inhibitor-based highly active antiretroviral therapyRole of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort.An update and review of antiretroviral therapy.Short communication: fasting increases serum concentrations of bilirubin in patients receiving atazanavir: results from a pilot study.Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapyInfluence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors.Incidence of atazanavir- associated adverse drug reactions in second -line drugs treated south Indian HIV-1 infected patients.Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors.Revealing the metabolic sites of atazanavir in human by parallel administrations of D-atazanavir analogs.Short-term effect of ritonavir-boosted atazanavir in hepatitis B and/or C co-infected, treatment-experienced HIV patients.HIV protease inhibitors activate the unfolded protein response and disrupt lipid metabolism in primary hepatocytes.Proteases and protease inhibitors in infectious diseases.Diversity-Oriented Synthesis of Cyclic Azapeptides by A3 -Macrocyclization Provides High-Affinity CD36-Modulating Peptidomimetics.Atazanavir/ritonavir: a valuable once-daily HIV protease inhibitor with little impact on lipid profile
P2860
Q28538860-4502AD1E-96FD-4EE7-AA7B-5318D1696C10Q28554577-0AD33367-2B3E-4FD3-8F24-3D266CD67902Q34150893-D1010F21-8D3F-4C9B-8C2A-E3C339DB0F35Q34159702-487F457D-DA81-4BB7-9DFC-2EF59A034F1AQ34307868-53CFD7A3-23A3-415F-B16D-80C0DB590341Q34702576-6C68C567-F0C5-4E17-B881-2F165ADE7AEBQ35025568-9EE76B6F-C68A-4776-8DB9-ECF5450BDA21Q36309602-885B2162-FD2E-45B7-9420-DC24FEA04158Q36545072-BB1DBBE6-A572-4B7C-B0E1-3D1A25649E96Q36634838-666E9083-91F2-4CBB-A537-3E2AD1D0CE9BQ36969787-844F9274-F27D-4594-A3AE-9997AF9D543AQ37113947-F29CCEAE-F7EB-4CF6-A10F-BFF15A037281Q37311978-A0633113-F3C6-4599-9062-CF2BA725A7A9Q37383940-55919A09-9434-47E6-AA67-D980774945F0Q42265837-817AFAC7-889D-4223-A63F-FBA255CE46FBQ42990611-9758048E-E52E-421A-8C8F-135BF5D32609Q44922052-EEA7A5EA-C620-4462-A6AF-07E021B41ABEQ47576680-5A81F721-3E46-4CDC-A8C2-D2E22E180B44Q48350838-FF36FF20-830F-44E7-9924-DA6462451210Q58291152-2659BF3E-777E-4BE1-8269-640DDCBEE295
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Atazanavir: new option for treatment of HIV infection.
@ast
Atazanavir: new option for treatment of HIV infection.
@en
type
label
Atazanavir: new option for treatment of HIV infection.
@ast
Atazanavir: new option for treatment of HIV infection.
@en
prefLabel
Atazanavir: new option for treatment of HIV infection.
@ast
Atazanavir: new option for treatment of HIV infection.
@en
P2860
P356
P1476
Atazanavir: new option for treatment of HIV infection.
@en
P2093
Steven D O'Marro
P2860
P304
P356
10.1086/420932
P407
P50
P577
2004-05-13T00:00:00Z